



## Pharmacy Formulary Updates for October 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in October 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Acuvail	T2
Advair Diskus	NC;QL
Alphagan P 0.01%	T2
Apadaz	NC;QL
Aptiom	T2
armodafinil	T3;PA;QL
Balversa	T2;PA
benzphetamine	T1
Bepreve	T2
Cablivi	T2
Climara Pro	T2
Combigan	T2;QL
CombiPatch	T2
Corlanor solution	NC
diethylpropion	T1
Duavee	T2
Duobrii	NC
FML Forte	T2
FML SOP ointment	T2
Fulphila	T3;PA;QL;SP
Fycompa	T2
Katerzia	NC
Lastacaft	T2
Letairis	NC;SP
Lumigan	T2;STPA
Mavenclad	T3;PA;QL;SP

<b>modafinil</b>	T2;PA;QL
<b>Piqray</b>	T2;PA;SP
<b>Polivy</b>	MB
<b>Prempro</b>	T2
<b>Provigil</b>	NC;QL
<b>Ranexa</b>	NC
<b>Rocklatan</b>	T3;STPA
<b>Roxybond</b>	T1;QL
<b>Simbrinza</b>	T2
<b>Spravato</b>	MB;PA
<b>Striverdi Respimat</b>	T2;QL
<b>tramadol ER biphasic tablets</b>	T1;QL
<b>Vyzulta</b>	T2;STPA
<b>Zulresso</b>	MB;PA

**Key:**

**MB:** Medical Benefit      **QL:** Quantity Limitation  
**NC:** Not covered          **SP:** Specialty Pharmacy - provided  
**NTM:** New-to-market      through CVS/specialty  
**PA:** Prior Authorization    **ST:** Step Therapy